NAYA Biosciences Common Stock Other Current Liabilities

NAYA Biosciences Common Stock (IVF) currently reports a other current liabilities of $3.2B as of March 2026. That compares with $12B in the prior-year period — down 73.8% year over year. Use the charts on this page to explore NAYA Biosciences Common Stock's other current liabilities history and peer comparisons.

NAYA Biosciences Common Stock's other current liabilities decreased from $12B to $3.2B — a 73.8% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

NAYA Biosciences Common Stock reported $3.2B in other current liabilities as of March 2026. That compares with $12B in the prior-year period — down 73.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current liabilities of $3.2B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for NAYA Biosciences Common Stock, and consider following IVF for alerts when major investors trade the stock.

NAYA Biosciences Common Stock is classified in the Healthcare sector. On other current liabilities, it currently shows $3.2B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing IVF with unrelated industries.